FORA Capital LLC Makes New $650,000 Investment in Enovis Co. (NYSE:ENOV)

FORA Capital LLC bought a new stake in Enovis Co. (NYSE:ENOV) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 15,103 shares of the company’s stock, valued at approximately $650,000.

Other large investors have also made changes to their positions in the company. Ridgewood Investments LLC acquired a new stake in Enovis during the 2nd quarter valued at $44,000. DekaBank Deutsche Girozentrale acquired a new stake in shares of Enovis in the third quarter valued at $55,000. Innealta Capital LLC bought a new position in shares of Enovis in the second quarter valued at about $65,000. Benjamin F. Edwards & Company Inc. lifted its position in Enovis by 28.1% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,691 shares of the company’s stock worth $76,000 after buying an additional 371 shares in the last quarter. Finally, FMR LLC grew its holdings in Enovis by 20.5% during the 3rd quarter. FMR LLC now owns 2,840 shares of the company’s stock worth $122,000 after acquiring an additional 484 shares during the last quarter. Institutional investors own 98.45% of the company’s stock.

Enovis Stock Up 1.5 %

NYSE:ENOV opened at $48.45 on Friday. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. Enovis Co. has a 12-month low of $38.27 and a 12-month high of $65.03. The stock’s fifty day simple moving average is $43.01 and its 200-day simple moving average is $44.90. The firm has a market capitalization of $2.71 billion, a P/E ratio of -22.12 and a beta of 1.91.

Enovis (NYSE:ENOV) last issued its earnings results on Wednesday, November 6th. The company reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.11. The firm had revenue of $505.22 million for the quarter, compared to analysts’ expectations of $504.44 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The company’s revenue was up 21.0% compared to the same quarter last year. During the same quarter last year, the business earned $0.56 earnings per share. Equities research analysts expect that Enovis Co. will post 2.79 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $65.00 target price on shares of Enovis in a research note on Thursday, November 7th. JMP Securities started coverage on Enovis in a report on Thursday, October 3rd. They set an “outperform” rating and a $62.00 price objective on the stock. Evercore ISI decreased their price objective on Enovis from $62.00 to $58.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 1st. Finally, JPMorgan Chase & Co. dropped their target price on Enovis from $53.00 to $50.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, Enovis presently has a consensus rating of “Moderate Buy” and an average target price of $67.00.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.